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Abstract
Background: Deep brain stimulation of the subthalamic nucleus (STN DBS) reduces Parkinson

RI
PT

disease (PD) motor symptoms but has unexplained, variable effects on mood.
Objective: The study tested the hypothesis that pre-existing mood and/or anxiety disorders or
increased symptom severity negatively affects mood response to STN DBS.

SC

Methods: Thirty-eight PD participants with bilateral STN DBS and on PD medications were
interviewed with Structured Clinical Interview for DSM-IV-TR Axis I Disorders (SCID) and
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completed Beck Depression Inventory (BDI) and Spielberger State Anxiety Inventory (SSAI)
self-reports. Subsequently, during OFF and optimal ON (clinical settings) STN DBS conditions
and while off PD medications, motor function was assessed with the United Parkinson Disease
Rating Scale (UPDRS, part III), and participants rated their mood with Visual Analogue Scales

TE
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(VAS), and again completed SSAI. VAS mood variables included anxiety, apathy, valence and
emotional arousal.

Results: STN DBS improved UPDRS scores and mood. Unexpectedly, PD participants

EP

diagnosed with current anxiety or mood disorders experienced greater STN DBS-induced
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C

improvement in mood than those diagnosed with remitted disorders or who were deemed as
having never met threshold criteria for diagnosis. BDI and SSAI scores did not modulate mood
response to STN DBS, indicating that clinical categorical diagnosis better differentiates mood
response to STN DBS than self-rated symptom severity. SCID diagnosis, BDI and SSAI scores
did not modulate motor response to STN DBS.

2

ACCEPTED MANUSCRIPT
STN DBS-induced changes in mood in PD
Conclusions: PD participants diagnosed with current mood or anxiety disorders are more
sensitive to STN DBS-induced effects on mood, possibly indicating altered basal ganglia
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circuitry in this group.
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Keywords: Parkison disease; subthalamic nucleus; deep brain stimulation; mood; mood
disorder; anxiety disorder
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Introduction
Twenty-five to 40% of individuals with Parkinson disease (PD) suffer from mood and
anxiety disorders that substantially impair quality of life [1-2]. While impairments in motor
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behavior in PD arise primarily from basal ganglia dysfunction [3], the neurobiological

underpinnings of comorbid psychiatric disorders in PD remain less clear. PD patients in the
advanced stages of the disease are particularly susceptible to psychiatric symptoms [1]. Since

SC

patients treated with subthalamic nucleus deep brain stimulation (STN DBS) typically have
advanced motor symptoms, they may fall within this vulnerable population. Although PD
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patients are frequently screened for current psychiatric disorders prior to STN DBS surgery [4],
they may have recovered at the time of screening from past illness, or may develop new
psychiatric symptoms after surgery as the disease progresses and treatment changes.
PD patients with STN DBS provide a unique opportunity to investigate the neural

TE
D

underpinnings of mood and anxiety disorders in PD. The STN may have substantial functional
heterogeneity, given its convergent inputs from and projections to motor, limbic and associative
cortical regions [5-8]. Growing evidence demonstrates that STN DBS, a therapy aimed at

EP

decreasing motor impairment and dopaminergic medication use in PD, also can alter mood [910]. Some studies have found reduced depression, apathy and psychiatric symptoms with

AC
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stimulators turned ON relative to OFF [11-13]. By contrast, case studies demonstrate that some
patients experience adverse changes in mood-related behavior with STN DBS, including fits of
laughter [14], hypomania [15], and severe transient depression [16-17]. Case reports [17] and
other studies [18-19], although not designed to experimentally test whether past psychiatric
disorders affect acute alterations in mood induced by STN DBS, highlight the importance of
considering the effects of past and current psychiatric disorders on the mood response to STN
DBS, which can be quite variable across PD patients.
4
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Here, we test whether past and present psychiatric history modulate the acute effects of
STN DBS on mood using a double-blind OFF/clinically optimal ON STN DBS experimental
design and well-validated measures of acute mood and behavioral change. In addition, PD
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participants refrained from dopaminergic medication overnight to reduce confounding the effects
of STN DBS on mood [12-14]. Based on past findings from our laboratory [11], we predicted
that STN DBS would induce beneficial acute effects on mood in PD participants without past or

SC

current mood or anxiety symptomatology. By contrast, we hypothesized that STN DBS would
acutely cause adverse alterations in mood in participants with remitted or current mood and
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anxiety symptoms based on evidence that preexisting psychiatric conditions may render PD
patients more susceptible to adverse mood alterations induced by STN DBS [17-19].
Materials and methods

TE
D

Participants

Thirty-eight participants with PD and bilateral STN-DBS were recruited from the
Washington University in St. Louis Movement Disorders Center. Six of these participants

EP

previously participated in a different study that measured mood response to STN DBS [11].
Participants were informed of all relevant risks and provided signed consent forms in accordance
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with the Declaration of Helsinki; the study was approved by the Washington University in St.
Louis Human Research Protection Office. Subjects were included based on clinically definite
diagnosis of PD [20-22], previously implanted bilateral STN-DBS electrodes and an absence of
neurological deficits including dementia, head injury or stroke. Details regarding the specific
surgical technique used to implant DBS electrodes and the programming paradigm can be found
elsewhere [23]. Soletra or Activa (Medtronic Inc.) pulse generators were used in all participants.
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DBS implants were previously optimized for motor benefit using monopolar stimulation prior to
recruitment into the study.
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PT

Localization of STN DBS electrode contacts
Pre-operative clinical MRIs were obtained with a Siemens Vision 1.5T scanner. MRIs
were aligned to post-operative computed tomography (CT) images and atlas registration was

SC

performed using a validated method [24]. The atlas location of each electrode contact was
visualized by overlaying the fused MRI-CT image (resliced to match the Mai atlas [25]) on Mai
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atlas slices where contact coordinates were plotted [24].
Behavioral protocol

The experimental procedure is diagrammed in Figure 1 and described below.
Initial Interview

TE
D

Prior to contact manipulation days, subjects were evaluated with their clinicallydetermined optimal STN DBS stimulation settings while on anti-parkinsonian medications
(optimal ON DBS, on medications) (see Figure 1). Presence of current or remitted mood or

EP

anxiety disorders was determined by administration of the Structural Clinical Interview for
DSM-IV-TR Axis I Disorders (SCID-I/NP [26]) by a movement disorders-trained
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neuropsychiatrist (KJB), except that the DSM-IV-TR causation criteria were ignored as
suggested by a consensus panel [27], e.g. Major Depressive Disorder was diagnosed rather than
Mood Disorder Due to Parkinson Disease. Current depressive and anxiety symptoms were
further assessed by 2 self-report questionnaires: the Beck Depression Inventory-II (BDI-II [28])
and the Spielberger State-Trait Anxiety Inventory (SSAI [29]).
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For some analyses (described below), the SCID was used to separate groups of
participants based on the presence of a threshold-level (as defined by the SCID and as
determined by the interviewing psychiatrist) current (threshold criteria met during the last
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PT

month) or remitted mood or anxiety disorder. The union of these two groups includes all
subjects who were diagnosed with past and/or current mood and/or anxiety disorders during the
Initial Interview. Due to low numbers of participants who were diagnosed with current mood

SC

disorders, we did not analyze these disorders separately. Diagnoses of participants with other
Axis I disorders (psychosis, substance abuse or dependence, somatoform or eating disorders) did
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not occur frequently enough in this sample for reliable data analysis.
Contact Manipulation Days

One to 7 days after the Initial Interview, participants underwent electrode contact

TE
D

manipulation days, during which they underwent a series of stimulation conditions including
OFF DBS and off PD medications, and clinically optimal settings ON DBS and off PD
medications.

Participants abstained from PD medications overnight prior to contact

EP

manipulation days and were in the ‘practical defined off state’ [30]. Participants continued to
take other medications, including psychiatric medications, and received optimal ON DBS until

AC
C

the first contact manipulation of the dayOptimal ON DBS, off PD medications was always the
last stimulation condition of the day. The order of other stimulation conditions was randomized
over 1-2 days (see Figure 1). In studies lasting 2 days, an OFF condition occurred on each day
and data collected from these conditions were averaged to obtain average OFF scores.

Motor

and mood outcomes were obtained 30-60 min following each contact manipulation (STN DBS
turned OFF or ON) [30].
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During each stimulation condition, motor signs were evaluated by a trained clinician
blind to stimulation condition using the motor subscale (part III) of the Unified Parkinson’s
Disease Rating Scale (UPDRS [31]). Self-rated mood was measured by visual analogue scales
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PT

(VAS [32]) and the SSAI (“state” only). VAS ratings were linked to the Circumplex Model of
emotion [33]. The following summary measures were used as dependent variables: valence and
emotional arousal (calculated as described in [34]), anxiety (average of responses to VAS items

SC

with anchors calm/nervous, relaxed/distressed, and calm/tense), and apathy (response to a VAS
with anchors motivated/apathetic). For clarity in graphic representation, anxiety and apathy

M
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scores were reversed by subtracting the raw score from 50 so that scores are centered at zero and
lower scores indicate lower anxiety or apathy.
Data analyses

TE
D

For analyses described below, dependent variables included UPDRS scores, VAS
anxiety, apathy, valence and emotional arousal scores, and SSAI anxiety scores, all obtained on
contact manipulation days, which included OFF DBS, off PD medication and optimal ON DBS,

EP

off PD medication sessions. Due to technical difficulties, one participant did not have SSAI
scores and another did not have VAS scores on contact manipulation days. Both of these

AC
C

participants were diagnosed with remitted mood disorders.
Acute effects of STN DBS on mood and motor behavior
Since UPDRS scores consist of ranks, a paired Wilcoxon signed ranks test was used to
test for differences in UPDRS scores between OFF DBS, off PD medication and optimal ON
STN DBS, off PD medication conditions; paired t-tests were used for VAS valence, anxiety,
apathy and arousal and SSAI anxiety variables.
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Modulation of STN DBS-induced changes in mood and motor behavior by psychiatric diagnosis
General linear model (GLM) univariate and non-parametric Kruskal-Wallis analyses of
variance (ANOVA) determined if age, disease duration, time between DBS surgery and Initial

RI
PT

Interview, proportion of participants currently taking psychiatric medications, SSAI scores
(during Initial Interview), BDI scores and race and gender distributions differed across 3 groups
of participants, including 1) participants diagnosed with a current mood and/or anxiety disorder

SC

(n = 15; these participants may also have remitted mood and/or anxiety disorders); 2) participants
diagnosed with a remitted mood or anxiety disorder (n = 11, no current diagnosis); and 3)

M
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participants deemed to have never met threshold criteria for a mood or anxiety disorder diagnosis
(n = 12). UPDRS , SSAI, VAS valence, VAS arousal, VAS anxiety and VAS apathy scores
obtained during the OFF DBS, off PD medications condition were also compared across groups
with Kruskal-Wallis or univariate ANOVA.

TE
D

Difference scores for all dependent variables were calculated by subtracting scores
obtained during OFF DBS, off PD medication from those obtained during optimal ON DBS, off
PD medication conditions. To avoid Type I error due to multiple comparisons and because VAS

EP

measures can be highly correlated with each other although they represent different aspects of
mood, two separate GLM multivariate ANOVA (MANOVA) were performed to determine
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whether diagnosis group, as described above, modulated STN DBS-induced VAS difference
scores. Since valence and arousal are the main constructs that represent emotional state in the
circumplex model of emotion [33] and are scored on the same scale, valence and arousal
difference scores were included as dependent variables in the first MANOVA.

The second

MANOVA included VAS anxiety and apathy difference scores as dependent variables.
Significant main effects of diagnosis group by MANOVA and subsequent univariate ANOVA
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were followed up with post hoc least square difference comparisons. STN DBS-induced
differences in SSAI and UPDRS scores were compared across the three diagnosis groups with a
univariate ANOVA and a non-parametric Kruskal-Wallis ANOVA, respectively.

RI
PT

Modulation of STN DBS-induced changes in mood and motor behavior by psychiatric symptom
severity

The influence of psychiatric symptom severity (measured by the BDI and SSAI during

SC

the Initial Interview) on STN DBS induced changes in VAS mood scores were tested in a

manner similar to the MANOVAs described in the paragraph above except that BDI or SSAI
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was treated as a covariate and all participants were included in the analyses instead of partitioned
into groups based on SCID diagnoses. Pearson’s r or Spearman’s ρ tested for relationships
between Initial Interview BDI or SSAI (from Initial Interview) scores and SSAI (from contact
manipulation days) and UPDRS difference scores, respectively.

TE
D

Relationships between STN DBS-induced changes in mood variables and motor behavior
To determine if STN DBS-induced changes in mood were related to changes in motor
function, correlations between mood and UPDRS difference scores were performed with

EP

Spearman’s ρ across all participants as well as within diagnostic groups.
The threshold for significance for all analyses was set at p ≤ 0.05, followed by Bonferroni

Results

AC
C

multiple comparisons correction when appropriate.

Participants

Participant characteristics are summarized in Table 1.
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Stimulation Parameters and Clinical Contact Locations
All participants had bilateral STN DBS with a monopolar configuration, with 185 Hz
frequency, 1.3 – 3.6 V amplitude, and 60 or 90 µs pulse width. STN DBS contact locations were

RI
PT

mostly localized to the posterior STN and adjacent regions (see Figure 2).
Acute Effects of STN DBS

SC

Relative to OFF DBS (off PD medications), optimal ON DBS (off PD medications)
improved motor symptoms (UPDRS: Z37 = -4.64, p < 0.001), self-rated anxiety (VAS: t36 = 4.45,

M
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p < 0.001; SSAI: t36 = 2.56, p < 0.05), apathy (VAS: t36 = 3.37, p < 0.01) and affective valence
(VAS: t36 = -4.72, p < 0.001), but did not affect affective arousal (VAS: t36 = 0.10, p = 0.93) (see
Figure 3). Multiple comparisons correction was not applied here because we predicted that STN
DBS would improve mood and motor function based on previous results from our laboratory

TE
D

[11].
Clinician Diagnoses and Symptom Severity

Tables 2 and 3 detail the distribution of subjects according to SCID diagnosis at the

EP

Initial Interview and psychiatric medication use.

AC
C

Modulation of STN DBS-induced changes in mood and motor behavior by psychiatric diagnosis
Participants with a current mood or anxiety disorder diagnosis (n = 15) did not differ
from those with remitted diagnoses (n = 11) or from participants deemed to have never met
threshold for diagnoses (n = 12) in age (p = 0.14), disease duration (p = 0.92; data missing for 1
participant in the group of participants in the non-diagnosed group), the number of months
between STN DBS surgery and the Initial Interview (p = 0.55), gender (p = 0.64), proportion of
participants currently taking psychiatric medications (p = 0.20), BDI scores (p = 0.20), or SSAI
11
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scores (p = 0.32). Racial distribution did differ among diagnosis groups (p < 0.05) (Table 4).
SSAI (p = 0.69), VAS valence (p = 0.39), VAS arousal (p = 0.45), VAS anxiety (p = 0.34), VAS
apathy (p = 0.21) and UPDRS (p = 0.12; see Table 4) scores obtained during the OFF DBS, off

RI
PT

PD medication condition did not differ across groups.

Participants with current mood or anxiety disorder diagnoses experienced increased STN
DBS-induced improvement in valence and anxiety (as measured by VAS) but not arousal or

SC

apathy compared to participants who were remitted or deemed to never have met threshold for
diagnosis. (Figure 4A-B, Table 5). STN DBS-induced changes in SSAI (F2,34 = 67.36, p = 0.47)

M
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U

and UPDRS (Χ236 = 1.03, p = 0.60) scores did not differ across the three diagnosis groups (data
not shown).

Modulation of STN DBS-induced changes in mood and motor behavior by psychiatric symptom
severity

TE
D

BDI-II scores obtained during the Initial Interview (optimal ON, on medications) did not
significantly modulate STN DBS-induced changes in any VAS measure (valence and arousal
MANCOVA: F2,34 = 0.90, p = 0.42; anxiety and apathy MANCOVA: F2,34 = 0.53, p = 0.59),

EP

SSAI (r37 = 0.22, p = 0.19) or UPDRS (ρ38 = 0.21, p = 0.21) scores (data not shown).

AC
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SSAI scores obtained during the Initial Interview (optimal ON, on medications) did not
significantly modulate STN DBS-induced changes in any VAS measure (valence and arousal
MANCOVA: F2,34 = 1.51, p = 0.24; anxiety and apathy MANCOVA: F2,34 = 0.16, p = 0.85),
SSAI (r37 = 0.09, p = 0.62) or UPDRS (ρ38 = 0.13, p = 0.44) scores (data not shown).
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Relationships Between Motor and Mood Responses to STN DBS
Across all participants (n = 37 excluding 1 participant each for VAS and SSAI analyses
due to missing scores), DBS-induced change in UPDRS scores did not significantly correlate

RI
PT

with DBS-induced change in anxiety (VAS: ρ37 = 0.04, p = 0.80; SSAI: ρ37 = 0.22, p = 0.18),
apathy (ρ37 = 0.11, p = 0.51), valence (ρ37 = -0.01, p = 0.97) or arousal (ρ37 = -0.06, p = 0.71)
(data not shown).

STN DBS-induced changes in self-rated VAS and SSAI scores also were not

SC

significantly related to DBS-induced change in UPDRS scores within any diagnostic group: 1)
participants who had current mood or anxiety diagnoses (n = 15) (ρ15 ≤ 0.51, p ≥ 0.05 for all

M
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correlations, data not shown); 2) participants diagnosed with remitted mood or anxiety disorders
(n = 10) (ρ10 ≤ 0.58, p ≥ 0.08 for all correlations, data not shown); 3) participants deemed to
never have had a threshold-level current or remitted mood or anxiety disorder (n = 12) (ρ12 ≤
0.18, p ≥ 0.57 for all correlations, data not shown). None of the correlational p-values survived

TE
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Bonferroni multiple comparisons corrections.
Discussion

The current study is the first analysis of the influence of mood or anxiety disorder

EP

diagnoses and self-reported psychiatric symptom severity on acute mood response to STN DBS

AC
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with a rigorous OFF vs. ON DBS experimental design while off PD medications. As expected,
STN DBS exerted acute positive effects on mood and motor behavior. Unexpectedly, PD
participants diagnosed with current mood or anxiety disorders were more sensitive to the
beneficial mood effects of STN DBS than those that did not meet threshold criteria for current
diagnosis.

Although STN DBS acutely improved motor manifestations, change in motor

function did not correlate with change in self-rated mood, suggesting that these effects occurred
independently of each other on an individual level. Taken together, these findings suggest that
13

ACCEPTED MANUSCRIPT
STN DBS-induced changes in mood in PD
current mood or anxiety disorders in PD alter the response of mood-related circuitry to STN
DBS and provide further evidence that the STN is a functionally heterogeneous brain region
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embedded in both sensorimotor and limbic circuitry [5-6,8].
Bilateral STN DBS acutely decreased self-reported anxiety and apathy while increasing
affective valence, but did not affect emotional arousal. These results support previous studies

SC

with similar experimental designs (ON vs. OFF stimulation, off PD medications) [11-13].
Replication of these findings both at a different clinical site from those in previous studies [12-
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13] and within our own laboratory [11] provides strong evidence for their validity. However, our
results do contrast with those of other studies [17-19] in which STN DBS induced adverse
effects on mood. However, these psychiatric adverse effects appear to occur in some but not all
PD patients in one study [19], and the other two are retrospective case reports [17-18].
Importantly, none of these studies [17-19] employed planned experiments designed to test for

TE
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acute changes in mood induced by STN DBS with an OFF control condition. Furthermore, as
described and as shown in Figure 2, the optimal STN DBS contact locations for participants in
our study were in and around the caudal dorsolateral STN region, which is the surgical target for

EP

STN DBS. Perhaps DBS at more ventral STN sites induces more profound and/or adverse
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effects on mood. Indeed, DBS of dorsal and ventral/ventromedial regions of the STN is widely
hypothesized to be disproportionately associated with alterations in motor behavior and mood,
respectively [35-38].

Contrary to our hypothesis, PD participants diagnosed with current mood or anxiety
disorders were more sensitive to STN DBS-induced improvements in valence and anxiety, as
measured by VAS, than those that were deemed to be remitted or to not have ever met threshold
criteria for diagnosis. It seems unlikely that the currently diagnosed group showed increased
14
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STN DBS-induced benefit in mood solely due to worse mood state at baseline since, relative to
the remitted group and participants that were deemed to have never met criteria for diagnosis,
they did not differ in BDI or SSAI scores during the Initial Interview or VAS or SSAI scores
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during the OFF DBS, off medication condition. Given that the study was designed to carefully
control for confounding effects such as placebo, lesion, and PD medications, it seems reasonable
to infer that PD participants diagnosed with current mood or anxiety disorders likely have

SC

disturbed brain circuitry that is acutely more responsive to STN DBS compared to PD
participants not currently diagnosed. In PD participants remitted for mood or anxiety disorders,
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this system may not be more responsive to STN DBS compared to participants never meeting
criteria for a mood or anxiety disorder diagnosis because the disorder occurred prior to the onset
of PD and/or disturbed circuitry may be recovered due to medication, other therapy, spontaneous
remission, possibly ongoing STN DBS or any combination of these factors. STN DBS may

TE
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acutely improve mood and anxiety by affecting neurotransmission and/or other signaling features
of the motor, associative and limbic circuitry that project to and/or receive input from the STN.
The exact mechanism by which high-frequency DBS exerts its effects remains unknown but it

EP

likely reduces disturbances in basal ganglia thalamocortical network activity by increasing both
excitatory and inhibitory signaling in the STN and adjacent fiber tracts [39]. In our study, DBS-
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induced improvements in self-rated mood and anxiety did not correlate with improved motor
function. Our findings suggest that optimized STN DBS can impact mood-related neural
circuitry in addition to and/or separately from its effects on motor symptoms.
Self-reported depressive and anxiety symptoms as measured by BDI and SSAI,
respectively, did not modulate mood response to STN DBS. BDI and SSAI scores also did not
differ between PD participants diagnosed with current mood or anxiety disorders and those
15
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without; nor did they differ between PD participants remitted for these disorders and those
deemed to have never met criteria for diagnosis. These results are surprising because study
participants completed these questionnaires at a maximum of one week prior to contact
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manipulation days, suggesting that relatively recent self-reported symptom severity is not
necessarily an accurate indicator of current or past threshold-level clinical symptoms of mood
and anxiety disorders in PD. Furthermore, our findings indicate that self-reported symptom

SC

severity does not predict mood or anxiety response to STN DBS while categorical clinical
diagnosis does. Interestingly, unlike VAS anxiety scores, psychiatric diagnosis did not modulate
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STN DBS-induced changes in SSAI scores. The causes and implications of these findings
deserve further study.

There are some limitations to this study. First, the majority of current SCID-diagnosed
psychiatric disorders in this study were anxiety disorders whereas past SCID-diagnosed

TE
D

psychiatric disorders were primarily mood disorders. The current study was not designed to test
for differential modulation of acute mood response by mood vs. anxiety disorders. The small
sample size and overlap of these symptoms in the same participants limits our ability to

EP

disentangle the influence of these two types of disorders. Indeed, all 3 participants diagnosed
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with current mood disorders were also diagnosed with current anxiety disorders.
Second, although participants were blinded to stimulation condition, fatigue and relief to
be nearly done with the study could contribute to improved mood and/or motor behavior since
the optimal ON condition was the last stimulation condition of the day. However, similar results
from our laboratory [11] and others [12-13] in which OFF and ON DBS conditions were
randomized indicate that observed acute effects of STN DBS on mood and anxiety in our study
are not an artifact of anticipated relief. Furthermore, visual inspection of the time course over
16
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the study day shows that, with the exception of arousal, mood and motor function do not appear
to improve over time (Figure 1, Appendix). It is also possible that DBS effects did not
completely dissipate during the OFF DBS, off medication condition, which may account for the
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lack of difference among diagnostic groups on the SSAI and VAS measures. Indeed, reversible
neuropsychiatric symptom rebounds are associated with gradualDBS (in regions other than STN)
battery depletion over time for treatment-resistant depression [40] and obsessive compulsive
Since we investigated acute rather than long-term DBS effects , long-term

SC

disorder [41].

wearing-off of DBS most likely does not account for diagnostic group differences in mood

M
AN
U

responsivity.

Finally, we controlled for PD medication but not psychiatric medication use. However,
as detailed in Table 2, a substantial number of PD participants who were diagnosed with
remitted or deemed to never have had a mood or anxiety disorder were taking psychiatric

TE
D

medications during the study and the proportion of participants with current diagnoses that were
taking psychiatric medications did not differ between these groups. Therefore, although future
studies should include investigation of psychiatric medication effects on behavior, it is unlikely

EP

that psychiatric medication is responsible for the positive modulation of mood response to STN

AC
C

DBS by current mood or anxiety disorder diagnoses.
Conclusions

PD participants diagnosed with current mood or anxiety disorders are more sensitive to
STN DBS-induced improvements in mood, a possible indication that basal ganglia circuitry may
be further altered in this group relative to those with remitted disorders or those deemed to have
never met threshold criteria for diagnosis. Importantly, our findings support the notion that the
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STN plays a role in both motor and psychiatric manifestations in PD and may serve as an
integration site for motor and limbic information as suggested by Haynes and Haber [5]. Future
studies should investigate the effect of prolonged STN DBS on mood with longitudinal studies as

RI
PT

well as the impact of baseline psychiatric symptomatology on the relationship between STN
DBS location and alterations in mood in PD.
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Table 1. Participant characteristics.

18 M, 20 F

Age (years)

63.0 (8.0)

RI
PT

Sex

Race

34 White, 1 Black, 3 Native American
13.6 (5.0)

Months from surgery to participation

15.5 (8.4)

SC

Duration of PD (years)

UPDRS Motor Score (OFF stimulation, off PD

33.9 (11.4)

BDI-II Score

M
AN
U

medication)

10.0 (5.5); range = 0-21

SSAI Score

30.4 (7.3); range = 20-45

Psychiatric Medication Type α, *

None, n = 15; SSRI, n = 8; SNRI, n = 1;

TE
D

TeCA, n = 3; TCA n = 2; nTCA n = 3;
BZD/BZD-like n = 11; Other n = 2

AC
C

EP

Mean (S.D.) shown.
α
, Participants may take more than 1 type of psychiatric medication.
*, data not obtained from 2 participants.
BDI-II, Beck Depression Inventory II; SSAI, Spielberger State Anxiety Inventory; SSRI,
selective serotonin reuptake inhibitor; SNRI, serotonin and norepinephrine inhibitor; TeCA,
tetracyclic antidepressant; TCA, tricyclic antidepressant; nTCA, non-tricyclic antidepressant
(bupropion); BZD, benzodiazepine; Other, neudexta and lamotrigine
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Table 2. Distribution of diagnosed disorders among PD participants in sample.
Number of participants

Number of participants taking
psychiatric medications*

Current mood disorder

3

3

Remitted mood disorder

15

13

No mood disorder ever

21

6

Current anxiety disorder

15

9

Remitted anxiety disorder

5

SC

RI
PT

SCID-I/NP Diagnoses α

M
AN
U

3

No anxiety disorder ever
19
9
, Participants may belong to more than 1 diagnostic category. *, data not obtained from 2
participants.

AC
C

EP
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D

α
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Table 3. Number of subjects diagnosed with various mood and anxiety disorders with the SCIDI/NP.α

Remitted

RI
PT

Mood Disorders
Major Depressive Disorder
Depressive Disorder NOS

10

2

3

1

1

0

3

6

0

4

0

4

1

1

1

0

Anxiety Disorders
Social Phobia
Specific Phobia
Anxiety Disorder NOS

M
AN
U

SC

Substance Induced

TE
D

Panic Disorder without Agoraphobia
Obsessive Compulsive Disorder
α

Current

AC
C

EP

, Participants may be diagnosed with more than one disorder. SCID, Structural Clinical
Interview for DSM-IV-TR Axis I Disorders; NOS, not otherwise specified.

26

ACCEPTED MANUSCRIPT
STN DBS-induced changes in mood in PD
Table 4. Participant characteristics by SCID diagnosis group.
Current Mood or
Remitted Mood or
Anxiety Disorder
Anxiety Disorder
Diagnosis (n = 15)
Diagnosis (n = 11)

5 M, 6 F

Age (years)

60.9 (7.7)

61.6 (9.3)

11 White, 1 Black, 3
Native American

11 White

Duration of PD (years)

13.8 (5.4)

13.1 (4.9)

Months from surgery to
participation

16.5 (7.1)

16.5 (10.3)

UPDRS Motor Score
(OFF DBS, off PD
medications)

37.9 (13.9)

BDI-II Score

11.9 (5.8)

M
AN
U

Race

7 M, 5 F

RI
PT

6 M, 9 F

SC

Sex

AC
C

EP

TE
D

SSAI Score
31.6 (6.9)
Mean (S.D.) shown. Data missing for a 1 participant.
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No Mood or Anxiety
Disorder Diagnosis
Ever (n = 12)

66.8 (6.4)

12 White

13.9α (5.0)

13.2 (8.2)

33.5 (9.6)

29.4 (7.9)

8.1 (3.8)

9.4 (6.1)

27.5 (5.3)

31.4 (9.0)
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Table 5. Results for MANOVAs: Diagnostic group modulation of STN DBS-induced changes in VAS measures. Current diagnosis n
= 15; remitted diagnoses n = 10; no diagnosis ever n = 12. Also, see Figure 4.
Main effect of Diagnostic
Group

Main effect of Diagnostic Group
by VAS measure

SC

Dependent Measure

VAS Valence and Arousal
Difference Scores

F4,68 = 2.56, p = 0.046

M
AN
U

Valence: F2,34 = 4.65, p = 0.016

Valence:
current vs. remitted, p = 0.009;
current vs. never, p = 0.027;
remitted vs. never, p = 0.575
Arousal: N/A (no main effect)

AC
C

VAS Anxiety and Apathy
Difference Scores

EP

TE
D

Arousal: F2,34 = 1.92, p = 0.162

post hoc LSD results

Anxiety: F2,34 = 5.61, p = 0.008

F4,68 = 3.27, p = 0.016
Apathy: F2,34 = 0.94, p = 0.401
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Anxiety:
current vs. remitted, p = 0.005;
current vs. never, p = 0.014;
remitted vs. never, p = 0.308
Apathy: N/A (no main effect)
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Figure Legends
Figure 1. Experimental procedure detailing interviews, self-report questionnaires, motor

RI
PT

assessment, and computer tasks (Visual Analogue Scales self-ratings) from which dependent
variables were obtained. Participants underwent contact manipulation conditions 1-7 days after
the Initial Interview. In the case of participants who underwent 2 days of stimulation conditions,

SC

OFF STN DBS dependent measure scores were obtained by averaging across both OFF

M
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U

conditions.

Figure 2. Three-dimensional distribution of clinically optimized STN DBS electrode contacts
for the sample studied (N = 38). They are presented (A) coronally and (B) sagittally, overlaid on
the Mai atlas [25], 17.2 mm posterior to the anterior commissure. For display purposes, a 0.75
mm radius sphere was centered on each contact location. Violet = STN; red spheres = right

TE
D

electrode contact locations; green spheres = left electrode contact locations.

Figure 3. Acute effects of STN DBS on mood and motor behavior. Relative to OFF DBS (off

EP

PD medications), clinically optimal STN DBS (off PD medications) (A) improved motor
symptoms, (B, D) decreased anxiety and apathy, and (C) increased valence (improved mood),

AC
C

but had no effect on emotional arousal. Mean + SEM shown. *, p < 0.05, **, p < 0.01, ***, p <
0.001 relative to OFF. VAS, visual analogue scale; SSAI, Spielberger State Anxiety Inventory;
UPDRS, United Parkinson’s Disease Rating Scale.

Figure 4. STN DBS-induced improvements in mood are greater in participants with current
anxiety or mood disorder diagnoses relative to participants with remitted diagnoses or deemed
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never to have met threshold criteria for diagnosis. Optimal ON, off medication STN DBSinduced improvements in self-rated (A) valence but not arousal and (B) anxiety but not apathy
were significantly elevated in currently diagnosed participants relative to remitted and never
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PT

diagnosed groups. Mean + SEM shown. *, p < 0.05 relative to no diagnosis ever; ##, p < 0.01
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relative to remitted diagnosis.
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Figure 1. Improved motor and mood scores, with the possible exception of arousal, during
optimal ON STN DBS, off medication do not appear to be due to the passage of time (relief to be
done for the day). Scores obtained during optimal ON STN DBS, off medication for each
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variable (A) UPDRS, (B) VAS anxiety, (C) VAS apathy, (D) VAS valence, (E) VAS arousal and
(F) SSAI anxiety were averaged over stimulation conditions over 2 contact manipulation days.
As part of a larger study, participants underwent up to 7 conditions of DBS in various regions of
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PT

the STN. There were up to 4 conditions a day. Optimal ON STN DBS was always the fourth
and last condition. Only the OFF and optimal ON STN DBS data is analyzed and presented in
the manuscript. Mean ± SEM shown. N = 33-38 per data point. Variability in n is due to lost
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data due to technical difficulties.
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Highlights
“Acute changes in mood induced by subthalamic deep brain stimulation in Parkinson disease are

RI
PT

modulated by psychiatric diagnosis” (original Ms. Ref. No.: BRS-D-14-00109) by SA
Eisenstein, WB Dewispelaere, MC Campbell, HM Lugar, JS Perlmutter, KJ Black, T Hershey.

Motor and mood responses to acute STN DBS were studied in 38 PD participants.

•

STN DBS improved motor and mood outcomes relative to OFF DBS.

•

Current psychiatric diagnosis was related to increased DBS-induced mood benefit.

•

Brain circuitry may be altered in PD participants with psychiatric diagnoses.
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